Eledon provides enrollment update for phase 2 bestow trial assessing tegoprubart for the prevention of organ rejection

Irvine, calif., july 29, 2024 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today announced that it has enrolled the 80th participant in its ongoing phase 2 bestow trial assessing tegoprubart for the prevention of rejection in kidney transplantation.

ELDN Ratings Summary

ELDN Quant Ranking